NCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
Clinical Trials
69 trialsNCT04903197 2026-01-22
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
NCT05336409 2025-12-18
ELiPSE-1
Century Therapeutics, Inc.
Phase 1 Terminated
NCT05169489 2025-10-21
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
Phase 1 Terminated
NCT05785715 2025-07-01
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie
Phase 2 Terminated
NCT04735471 2025-06-18
GLEAN-1
Adicet Therapeutics
Phase 1 Terminated
NCT04982471 2025-03-11
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Celgene
Terminated
NCT02413489 2025-02-04
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT03768505 2024-12-31
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
MEI Pharma, Inc.
Phase 2 Terminated
NCT00597909 2024-12-17
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Amgen
Phase 2 Terminated
NCT04745832 2024-11-04
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
Phase 3 Terminated
NCT04358458 2024-10-24
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Genmab
Phase 1/2 Terminated
NCT04934670 2024-08-27
2002
Xenikos
Phase 3 Terminated
NCT04806035 2024-07-31
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
TG Therapeutics, Inc.
Phase 1 Terminated
NCT04082936 2024-07-24
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
IGM Biosciences, Inc.
Phase 1/2 Terminated
NCT05720052 2024-07-18
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT02384954 2024-07-03
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Altor BioScience
Phase 1/2 Terminated
NCT04762160 2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Phase 2 Terminated
NCT03571828 2024-03-22
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Amgen
Phase 1 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT04699461 2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2 Terminated
NCT02204982 2023-09-28
DYNAMO + R
SecuraBio
Phase 3 Terminated
NCT02391545 2023-09-28
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
SecuraBio
Phase 1/2 Terminated
NCT02536300 2023-08-14
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Gilead Sciences
Phase 3 Terminated
NCT05222516 2023-08-08
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
OM Pharma SA
Phase 2 Terminated
NCT03828448 2023-07-24
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
TG Therapeutics, Inc.
Phase 2 Terminated
NCT02440685 2023-06-07
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Phase 1/2 Terminated
NCT02914938 2023-05-09
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
MEI Pharma, Inc.
Phase 1 Terminated
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT04804254 2023-02-03
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
AbbVie
Phase 1 Terminated
NCT04782609 2022-11-17
Glio
Samus Therapeutics, Inc.
Phase 1 Terminated
NCT02793583 2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT03738423 2022-06-10
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT04844086 2022-05-18
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
Eden BioCell Ltd.
Phase 1 Terminated
NCT02872298 2022-04-12
RELIEF-1
Nuvaira, Inc.
Phase NA Terminated
NCT04803227 2022-01-04
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Histogen
Phase 1 Terminated
NCT01510184 2021-12-16
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03135262 2021-12-07
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03736967 2021-11-01
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03685344 2021-10-26
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
ADC Therapeutics S.A.
Phase 1 Terminated
NCT01662102 2021-10-04
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00003056 2021-05-06
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Takeda
Phase 3 Terminated
NCT04342117 2021-03-17
REAL
SecuraBio
Terminated
NCT01103037 2020-12-19
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
Novartis
Phase 2 Terminated
NCT01799889 2020-11-19
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 2 Terminated
NCT03037645 2020-10-19
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Sunesis Pharmaceuticals
Phase 1/2 Terminated
NCT02501473 2020-09-09
MK-3475-174
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Terminated
NCT03436771 2020-05-04
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
Juno Therapeutics, a Subsidiary of Celgene
Terminated
NCT01805791 2020-01-02
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
Hutchmed
Phase 3 Terminated